Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurol Sci ; 25 Suppl 1: S16-9, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15045614

RESUMO

Dizziness and vertigo are common complaints in patients referred for neurological evaluation. With a basic understanding of vestibular physiology and proper examination techniques, a correct diagnosis can generally be made at the bedside. This article reviews the most common peripheral and central vestibular syndromes as well as the key elements of the bedside vestibular system examination.


Assuntos
Exame Neurológico/normas , Vertigem/diagnóstico , Vertigem/fisiopatologia , Doenças Cerebelares/patologia , Doenças Cerebelares/fisiopatologia , Aqueduto da Cóclea/patologia , Aqueduto da Cóclea/fisiopatologia , Diagnóstico Diferencial , Epilepsia/complicações , Epilepsia/fisiopatologia , Humanos , Doença de Meniere/patologia , Doença de Meniere/fisiopatologia , Neuroma Acústico/patologia , Neuroma Acústico/fisiopatologia , Vertigem/etiologia , Nervo Vestibular/fisiopatologia
2.
Artigo em Inglês | MEDLINE | ID: mdl-11041543

RESUMO

1. Conflicting reports are available regarding the sensitivity of patients with Dementia with Lewy bodies (DLB) to risperidone. 2. The authors studied a rare familial case of probable DLB, who developed a documented episode of neuroleptic malignant syndrome (NMS) following the exposure to risperidone. Previously, the patient had had an episode of NMS on trifluoperazine. 3. The discontinuance of risperidone, in combination with a mild increase of dopaminergic therapy, led to a complete recovery in few days. 4. In patients with DLB, a continued vigilance for extrapyramidal side effects, including NMS, would be advisable during the use of risperidone.


Assuntos
Antipsicóticos/efeitos adversos , Doença por Corpos de Lewy/tratamento farmacológico , Síndrome Maligna Neuroléptica/fisiopatologia , Risperidona/efeitos adversos , Antipsicóticos/uso terapêutico , Feminino , Humanos , Doença por Corpos de Lewy/genética , Pessoa de Meia-Idade , Síndrome Maligna Neuroléptica/etiologia , Risperidona/uso terapêutico
3.
Arch Ophthalmol ; 113(2): 185-9, 1995 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-7532394

RESUMO

OBJECTIVE: To determine the percent of cases with all primary forms of exudative age-related macular degeneration that are eligible for treatment by the Macular Photocoagulation Study (MPS) guidelines in a retina clinic serving both as a primary care center and as a referral center. DESIGN: Fluorescein angiograms of patients with age-related macular degeneration examined at the Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, during a 5-year period (1985 to 1990) were randomly selected and reviewed. Angiograms showing all forms of exudative age-related macular degeneration were eligible. The first 100 eligible angiograms identified constituted the study series and were classified into four groups: active choroidal neovascularization (CNV), pigment epithelium detachment, hemorrhage, and disciform scars. The active CNVs were further divided into three subgroups: classic (well defined), occult (poorly defined), and combined. Eligibility for laser treatment was determined exclusively with use of the published MPS recommendations for treatment of extrafoveal, juxtafoveal, and subfoveal membranes. RESULTS: There were 10 cases in the pigment epithelium detachment group, 11 cases in the hemorrhagic group, and 16 cases with disciform scars. All of these 37 cases were ineligible for treatment by MPS guidelines. Sixty-three eyes had active membranes; 37 were classic CNVs (eight extrafoveal, seven juxtafoveal, and 22 subfoveal). All extrafoveal and juxtafoveal CNVs were found to be eligible for laser treatment. Eleven membranes of the subfoveal group were larger than 2 disc areas, a size for which the MPS did not demonstrate benefit from laser treatment. There were 19 membranes in the strictly occult CNV subgroup, all of them untreatable by MPS criteria. Seven cases had both occult and classic CNV, and all were larger than 3.5 disc areas and therefore ineligible for treatment. Overall, 26 cases were eligible for treatment by strict MPS criteria; these constitute 26% of the whole series and 41% of the active CNV cases in the series. CONCLUSIONS: Our results indicate that the MPS guidelines for laser treatment are applicable only to a minority of the cases with exudative age-related macular degeneration presenting to our clinic. Further studies should be conducted to identify additional treatment modalities for this common eye disease.


Assuntos
Definição da Elegibilidade , Fotocoagulação a Laser , Macula Lutea/cirurgia , Degeneração Macular/cirurgia , Corioide/irrigação sanguínea , Exsudatos e Transudatos , Angiofluoresceinografia , Humanos , Degeneração Macular/etiologia , Neovascularização Patológica/etiologia , Neovascularização Patológica/cirurgia , Guias de Prática Clínica como Assunto , Descolamento Retiniano/etiologia , Descolamento Retiniano/cirurgia , Hemorragia Retiniana/etiologia , Hemorragia Retiniana/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...